Special Issue

Antibiotic Transport in Gram-Negative Bacteria

Message from the Guest Editor

Gram-negative bacteria have been classified from the WHO as the most critical priorities for the search of new anti-infectives. The pharmacological targets in Gram-negative bacteria are difficult to address. Though modern sequencing techniques have given access to innumerable potential new targets, the molecules identified with high-throughput screening campaigns are not able to be effective against bacteria **in vivo**. The singularity of Gram-negative species is a complex cell wall composed by an additional tick outer membrane with asymmetric composition. The outer membrane and its constituents (porins, specific transporters, and efflux pumps) are able to modulate the transport of molecules in and out, representing a complex filtering system for any molecule. This Special Issue seeks manuscript submissions that further our understanding of molecular transport and eventually accumulation in Gram-negative species, in terms of structures involved an their mechanism of functioning, as well as with methods to measure accumulations and predictive tools

Guest Editor

Dr. Matteo Ceccarelli

Department of Physics, Università degli Studi di Cagliari and IOM/CNR, 09124 Cagliari, CA, Italy

Deadline for manuscript submissions

closed (31 January 2022)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/61821

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI